Source:http://linkedlifedata.com/resource/pubmed/id/17451461
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-1-14
|
| pubmed:abstractText |
Uterine serous papillary carcinoma (USPC) is a rare and highly malignant form of endometrial cancer (EC) characterized by early metastasis, chemoresistance, and high mortality rate. Little is known about USPC tumorigenesis even if recently a HER-2/neu role has been suggested in its development and progression. The aim of the present study was to evaluate HER-2 expression by immunohistochemistry (IHC) in 12 USPC formalin-fixed, paraffin-embedded (FFPE) samples. Moreover, we looked at the correlation between HER-2 protein expression and HER-2/neu gene amplification by fluorescence in situ hybridization (FISH), other than HER-2/neu messenger RNA expression by quantitative real-time reverse transcription (RT)-polymerase chain reaction (PCR). Finally, these results have been compared with commonly evaluated clinical features in EC patients, in order to define the potential prognostic value of HER-2/neu overexpression in USPCs. A high expression of HER-2 protein by IHC was noted in 2 of 12 patients (16.6%), and the same cases showed specific HER-2/neu gene amplification by FISH. All the samples investigated displayed a perfect concordance between IHC and FISH data. Five (41.6%) of 12 tumors demonstrated polysomy of chromosome 17 and, focusing on the 2 USPCs that showed HER-2/neu overexpression, one of them (50%) was polysomic for chromosome 17. All the other USPC cases (58.4%) showed to be disomic for chromosome 17. Quantitative RT real-time PCR performed on complementary DNA obtained from all FFPE USPC samples showed a complete correlation with FISH and IHC data. Moreover, HER-2/neu overexpression was associated with a poorer overall survival and a very low relapse-free survival time, thus being considered a candidate marker of worse overall prognosis in USPC. The use of trastuzumab (Herceptin), a monoclonal antibody directed against HER-2/neu, for the therapy of patients with HER-2/neu-positive USPCs should be further investigated in clinical trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1525-1438
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
14-21
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:17451461-Aged,
pubmed-meshheading:17451461-Aged, 80 and over,
pubmed-meshheading:17451461-Cystadenocarcinoma, Papillary,
pubmed-meshheading:17451461-Female,
pubmed-meshheading:17451461-Gene Amplification,
pubmed-meshheading:17451461-Humans,
pubmed-meshheading:17451461-Immunoenzyme Techniques,
pubmed-meshheading:17451461-In Situ Hybridization, Fluorescence,
pubmed-meshheading:17451461-Lymph Nodes,
pubmed-meshheading:17451461-Middle Aged,
pubmed-meshheading:17451461-Neoplasm Invasiveness,
pubmed-meshheading:17451461-Paraffin Embedding,
pubmed-meshheading:17451461-Prognosis,
pubmed-meshheading:17451461-Receptor, erbB-2,
pubmed-meshheading:17451461-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17451461-Survival Rate,
pubmed-meshheading:17451461-Uterine Neoplasms
|
| pubmed:articleTitle |
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
|
| pubmed:affiliation |
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Brescia, Italy. fodicino@tiscali.it
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|